T2	control 283 319	6 cycles of epidoxorubicin/docetaxel
T4	total-participants 396 406	Forty-five
T5	outcome-Measure 702 743	pathological complete response (pCR) rate
T7	outcome 862 865	pCR
T8	iv-bin-percent 878 881	10%
T9	iv-bin-abs 883 886	two
T10	intervention-participants 890 892	20
T11	cv-bin-percent 912 915	36%
T12	cv-bin-abs 917 921	nine
T13	control-participants 925 927	25
T14	outcome 988 1032	Breast-conserving surgery could be performed
T15	iv-bin-percent 1036 1039	70%
T16	iv-bin-abs 1041 1043	14
T17	intervention-participants 1047 1049	20
T18	cv-bin-percent 1069 1072	76%
T19	cv-bin-abs 1074 1076	19
T20	control-participants 1080 1082	25
T21	outcome 1106 1145	Axillary lymph node status was negative
T22	iv-bin-percent 1149 1152	45%
T23	iv-bin-abs 1154 1158	nine
T24	intervention-participants 1162 1164	20
T25	cv-bin-percent 1181 1184	52%
T26	cv-bin-abs 1186 1188	13
T27	control-participants 1192 1194	25
T28	eligibility 407 453	patients eligible for neoadjuvant chemotherapy
T1	intervention 68 96	epidoxorubicin and docetaxel
T3	outcome-Measure 774 808	rates of breast-conserving surgery
T6	outcome-Measure 817 843	axillary lymph node status
